NCT07002476RecruitingPhase 3
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
EAST-LDL is a prospective, multicenter, randomized, open-label clinical trial with blinded endpoint assessment evaluating whether early intensive lipid lowering with the PCSK9 inhibitor recaticimab, administered before endovascular therapy, improves functional outcome in patients with acute ischemic stroke due to anterior-circulation large-vessel occlusion. Participants are randomized to recaticimab plus guideline-recommended standard of care or standard of care alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0-2 at 90 ± 7 days.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 978 (estimated)
- First submitted
- 25 May 2025
- Start date
- 19 Jun 2025
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Shanghai East Hospital
- Diseases
- Stroke
- NCT number
- NCT07002476
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 978
- From 19 Jun 2025 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment;
- Severe, concomitant non-cardiovascular disease expected to reduce life expectancy to less than 3 months;
Other illness
- Pre-existing functional impairment, with mRS score \>2;
- Patients who are allergic to PCSK9 inhibitors;
- Other conditions deemed unsuitable for inclusion in the clinical study by the investigator.
Lab values
- Severe renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m2 at final screening;
- Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the upper limit of normal;
Other
- ASPECTS score ≤5 on cranial CT imaging;
- Pregnant or lactating women;
- Patients who are participating in other clinical trials;
Who the study is looking for
- Adults (age 18 years and older);
- Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2);
- Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines;
- Provision of informed consent by the patient or his/her legally authorized representative (or by an appropriate agent according to local requirements).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai East Hospital, Tongji University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.